Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma

Despite recent therapeutic advances that have doubled the median survival time of patients with multiple myeloma (MM), intratumor genetic heterogeneity contributes to disease progression and emergence of drug resistance. MicroRNAs (miRs), are noncoding small RNAs that play important roles in the reg...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Res
Main Authors: Zhao, Jian-Jun, Chu, Zhang-Bo, Hu, Yu, Lin, Jianhong, Wang, Zhongqiu, Jiang, Meng, Chen, Ming, Wang, Xujun, Kang, Yue, Zhou, Yangsheng, Ni Chonghaile, Triona, Johncilla, Melanie E., Tai, Yu-Tzu, Cheng, Jin Q., Letai, Antony, Munshi, Nikhil C., Anderson, Kenneth C., Carrasco, Ruben D.
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4609291/
https://ncbi.nlm.nih.gov/pubmed/26249174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-0457
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares